Valitor is pioneering a novel approach in the field of ophthalmic medicines through its proprietary Multivalent Polymer (MVP) technology platform. This innovative platform allows for the creation of macromolecular entities that can be engineered to enhance therapeutic potency, durability, and safety. By utilizing multivalent biopolymers, Valitor can load multiple copies of bioactive molecules, enabling independent control over various drug attributes such as pharmacokinetics, target engagement, and therapeutic durability. This technology aims to address the limitations of traditional biologic medicines, particularly in the treatment of vision-threatening diseases, by providing long-acting therapies that improve patient outcomes.

The company's lead candidate, VLTR-559, is being developed as a long-acting treatment for wet age-related macular degeneration (AMD). This condition, characterized by the growth of abnormal blood vessels in the eye, currently requires frequent intravitreal injections of anti-VEGF therapies. Valitor's VLTR-559 aims to reduce the treatment burden by enabling dosing only twice a year while maintaining efficacy. Preclinical studies have shown that VLTR-559 exhibits significantly improved potency and tissue retention compared to existing therapies, demonstrating its potential to revolutionize treatment protocols in ophthalmology and possibly expand into other therapeutic areas such as cancer and joint diseases.

United States

Valitor, Inc. is a biotechnology company founded to develop advanced, protein-based drugs. Using our core technology, we can modify existing biological therapies to achieve substantial control over their pharmacological properties. Our mission is to develop a new generation of biologic therapies that will reduce the costs associated with effective treatment of these diseases. We also aim to improve the patients’ quality of life by reducing the required frequency of therapeutic administration. We have initiated a pipeline of drug products that will be used to treat a variety of diseases currently imposing a significant financial burden on the nation’s healthcare system.

Valitor

Company Details